Cidel Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Cidel Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	33,042 +345	+1%	+$19.8K	0.09%	120
2026 Q1	$1.98M	Buy	32,697 +5,551	+20%	+$324K	0.11%	102
2025 Q4	$1.46M	Buy	27,146 +2,700	+11%	+$130K	0.1%	106
2025 Q3	$1.1M	Buy	24,446 +1,960	+9%	+$91.5K	0.06%	120
2025 Q2	$1.04M	Buy	22,486 +666	+3%	+$32.7K	0.06%	123
2025 Q1	$1.33M	Buy	21,820 +840	+4%	+$49K	0.09%	100
2024 Q4	$1.19M	Buy	20,980 +1,133	+6%	+$63.3K	0.08%	105
2024 Q3	$1.03M	Buy	19,847 +2,446	+14%	+$115K	0.07%	115
2024 Q2	$723K	Buy	17,401 +3,250	+23%	+$145K	0.06%	139
2024 Q1	$767K	Buy	14,151 +2,111	+18%	+$108K	0.06%	136
2023 Q4	$618K	Buy	+12,040	New	+$632K	0.03%	162
2019 Q3	–	Sell	-4,650	Closed	-$211K	–	122
2019 Q2	$211K	Hold	4,650	–	–	0.01%	103
2019 Q1	$222K	Buy	+4,650	New	+$232K	0.01%	121

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Cidel Asset Management's BMY Position: Q2 2026 in Review

Cidel Asset Management increased its Bristol-Myers Squibb (BMY) stake by 1.1% in Q2 2026, buying an estimated $19.8K and bringing the position to 33,042 shares worth $1.9M. The position accounts for 0.09% of the portfolio, ranked #120.

Cidel Asset Management first reported a position in BMY in Q1 2019 and has held it in 13 quarters since. The position peaked at $1.98M in Q1 2026. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Cidel Asset Management held 33,042 shares of Bristol-Myers Squibb worth $1.9M as of Q2 2026.
Cidel Asset Management bought 345 Bristol-Myers Squibb shares in Q2 2026, an estimated $19.8K.
Bristol-Myers Squibb made up 0.09% of Cidel Asset Management's portfolio in Q2 2026, its #120 holding.
Cidel Asset Management first reported a position in Bristol-Myers Squibb in Q1 2019 and has held it in 13 quarters since.
Cidel Asset Management's Bristol-Myers Squibb position peaked at $1.98M in Q1 2026.
878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Cidel Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.